Published in Lab Law Weekly, November 27th, 2009
$2.7 million, compared with $4.5 million for the third quarter of
2008. -- Gross margin for the third quarter of 2009 was 71%, compared with 61%
for the third quarter of 2008, reflecting higher consumable sales as a
percentage of the company's product sales. -- Research and development expenses were $8.5 million for the third
quarter of 2009, compared with $7.1 million for the same period in the
prior year. Research and development expenses for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.